Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 1/20 | 0.81 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3383972 | 0.94 | PTGFR (0.72) | PTGFRHSD11B1MMP9 | |
| SCHEMBL3382796 | 0.90 | PTGFR (0.90) | PTGFRHSD11B1MMP2MMP9 | |
| Ebopiprant SCHEMBL18055678 | 0.90 | PTGFR (1.00) | PTGFRHSD11B1MMP2MMP9 | |
| Ebopiprant SCHEMBL26667891 | 0.90 | PTGFR (1.00) | PTGFRHSD11B1MMP2MMP9 | |
| Ebopiprant SCHEMBL26496347 | 0.90 | PTGFR (1.00) | PTGFRHSD11B1MMP2MMP9 | |
| Ebopiprant SCHEMBL24797015 | 0.90 | PTGFR (1.00) | PTGFRHSD11B1MMP2MMP9 | |
| Ebopiprant SCHEMBL19077960 | 0.90 | PTGFR (1.00) | PTGFRHSD11B1MMP2MMP9 | |
| Ebopiprant SCHEMBL18055682 | 0.90 | PTGFR (1.00) | PTGFRHSD11B1MMP2MMP9 | |
| Ebopiprant SCHEMBL21142449 | 0.90 | PTGFR (1.00) | PTGFRHSD11B1MMP2MMP9 | |
| Ebopiprant SCHEMBL18055684 | 0.89 | PTGFR (0.98) | PTGFRHSD11B1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487442-B1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | MERCK SERONO SA (CH) | 2010-12-01 | — | — | EP | claimed |
| US-20050215605-A1 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | MERCK SERONO SA (CH) | 2005-09-29 | — | — | US | claimed |
| US-20240024294-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR | XOMA (US) LLC | 2024-01-25 | — | — | US | disclosed |
| US-20230372306-A1 | COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR | XOMA (US) LLC | 2023-11-23 | — | — | US | disclosed |
| US-11534428-B1 | Compositions and methods for delaying the incidence of labor | XOMA (US) LLC (US) | 2022-12-27 | — | — | US | disclosed |
| US-8415480-B2 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor | MERCK SERONO SA (CH) | 2013-04-09 | — | — | US | disclosed |
| US-8415480-B2 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor | MERCK SERONO SA (CH) | 2013-04-09 | — | — | US | disclosed |
| US-8415480-B2 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor | MERCK SERONO SA (CH) | 2013-04-09 | — | — | US | disclosed |
| EP-1487442-B1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | MERCK SERONO SA (CH) | 2010-12-01 | — | — | EP | disclosed |
| EP-1487442-B1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | MERCK SERONO SA (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2008-10-16 | — | — | US | disclosed |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2008-10-16 | — | — | US | disclosed |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2008-10-16 | — | — | US | disclosed |
| US-20050215605-A1 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | MERCK SERONO SA (CH) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372306-A1 | COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR | PGF, TRPV2, TRPV3 | PTGFR 9/4885HSD11B1 2075/4885MMP2 3333/4885 |
| US-20240024294-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR | PGF, PTGS1, PTGIR | PTGFR 7/4885HSD11B1 2481/4885MMP2 2439/4885 |
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | PTGER4, PTGER2, PTGER1 | PTGFR 9/4885HSD11B1 2095/4885MMP2 2710/4885 |
| US-11534428-B1 | Compositions and methods for delaying the incidence of labor | PGF, TRPV2, TRPV3 | PTGFR 9/4885HSD11B1 2075/4885MMP2 3333/4885 |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | PTGER4, PTGER2, PTGER1 | PTGFR 9/4885HSD11B1 2095/4885MMP2 2710/4885 |
| US-20050215605-A1 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | TBXA2R, CNR2, PTGDR | PTGFR 16/4885HSD11B1 2705/4885MMP2 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.